Finance

Lists
1NBIX:BIT
Neurocrine Biosciences, Inc
€135.80
-2.65%
(-3.70) 1D
Sep 3, 4:19:36 PM GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for 1NBIX...
Mkt. cap
15.83B
Avg. vol.
7.00
Volume
0.00
52-wk high
€164.10
52-wk low
€101.00
No. of employees
2K
Mkt. cap
15.83B
Avg. vol.
7.00
Volume
0.00
52-wk high
€164.10
52-wk low
€101.00
No. of employees
2K
Profile
Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine was approved in the US to treat adults with tardive dyskinesia. The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia and with a partner for endometriosis and uterine fibroids. Wikipedia
About Neurocrine Biosciences, Inc
CEOKevin C. Gorman
Employees2.5K
Founded1992
HeadquartersSan Diego, California, United States
SectorBiotechnology
Websiteneurocrine.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
794.90M
805.50M
814.50M
959.00M
Cost of goods sold
264.00M
275.80M
310.00M
346.70M
Cost of revenue
264.00M
275.80M
310.00M
346.70M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
291.60M
302.50M
318.50M
383.10M
Operating expense
291.60M
302.50M
318.50M
399.50M
Total operating expenses
555.60M
578.30M
628.50M
746.20M
Operating income
239.30M
227.20M
186.00M
212.80M
Other non operating income
-
-
-
-
EBT including unusual items
291.80M
239.40M
246.80M
162.20M
EBT excluding unusual items
261.50M
253.00M
214.10M
222.30M
Income tax expense
82.30M
85.70M
48.90M
17.80M
Effective tax rate
28.20%
35.80%
19.81%
10.97%
Other operating expenses
-
-
-
-
Net income
209.50M
153.70M
197.90M
144.40M
Net profit margin
26.36%
19.08%
24.30%
15.06%
Earnings per share
2.17
1.88
1.94
2.85
Interest and investment income
22.20M
25.80M
28.10M
12.40M
Interest expense
-
-
-
-2.90M
Net interest expenses
22.20M
25.80M
28.10M
9.50M
Depreciation and amortization charges
-
-
-
-
EBITDA
247.00M
234.70M
193.30M
237.60M
Gain or loss from assets sale
-
-
-28.60M
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps